Patent 7423024 was granted and assigned to Merrimack Pharmaceuticals on September, 2008 by the United States Patent and Trademark Office.
Disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof.